UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 88

Sortiert nach

The value of anticancer drugs - a regulatory view

Nature reviews. Clinical oncology, 2022-03, Vol.19 (3), p.207-215

2022

Volltextzugriff (PDF)

5024 POSTER DISCUSSION Clinically Used Breast Cancer Markers are Heterogeneous Throughout Tumour Progression

European journal of cancer (1990), 2011, Vol.47, p.S337-S338

2011

Volltextzugriff (PDF)

Discordance in hormone receptor status in breast cancer during tumor progression

JOURNAL OF CLINICAL ONCOLOGY, 2010-05, Vol.28 (15_suppl), p.1009-1009

2010

Volltextzugriff (PDF)

Uptake of aromatase inhibitors (AI) and trastuzumab (T) during the first 5 years after market introduction. A North American and European comparison

JOURNAL OF CLINICAL ONCOLOGY, 2008, Vol.26 (15_suppl), p.6536-6536

2008

Volltextzugriff (PDF)

Abstract S3-5: Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.S3-S3-5

2010

Volltextzugriff (PDF)

Inter- and intra-country variations in the use of trastuzumab in Norway, Spain and Sweden

JOURNAL OF CLINICAL ONCOLOGY, 2007, Vol.25 (18_suppl), p.1069-1069

2007

Volltextzugriff (PDF)

HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients

JOURNAL OF CLINICAL ONCOLOGY, 2007, Vol.25 (18_suppl), p.1023-1023

2007

Volltextzugriff (PDF)

398 INVITED Should a Biopsy Be Done in Each Patient With a Suspicion of Metastatic Relapse?

European journal of cancer (1990), 2011, Vol.47, p.S87-S87

2011

Volltextzugriff (PDF)

Does access to cancer drugs relate to survival benefit? A European study in countries with different economic status

JOURNAL OF CLINICAL ONCOLOGY, 2017, Vol.35 (15_suppl), p.6535-6535

2017

Volltextzugriff (PDF)

Access to cancer drugs in Europe years 2005-2014

Annals of oncology, 2016-10, Vol.27, p.vi475-vi475

2016

Volltextzugriff (PDF)

Access to cancer drugs in Europe years 2005-2014

JOURNAL OF CLINICAL ONCOLOGY, 2016, Vol.34 (15_suppl), p.e18015-e18015

2016

Volltextzugriff (PDF)

Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2601-2608

2012

Volltextzugriff (PDF)

Risk-adjusted benchmarking of long-term overall survival in patients with HER2-positive early-stage Breast cancer: A Swedish retrospective cohort study

Breast (Edinburgh), 2023-08, Vol.70, p.18-24

2023

Volltextzugriff (PDF)

Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting

Breast (Edinburgh), 2016-10, Vol.29, p.140-146

2016

Volltextzugriff (PDF)

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

Breast cancer research and treatment, 2011-01, Vol.125 (2), p.553-561

2011

Volltextzugriff (PDF)

540 Uptake of trastuzumab (T) in selected European countries during the first 9 years after market introduction

European journal of cancer supplements, 2010, Vol.8 (3), p.217-217

2010

Volltextzugriff (PDF)

Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study

European journal of cancer care, 2022-09, Vol.31 (5), p.e13626-n/a

2022

Volltextzugriff (PDF)

Planning for return to work during the first year after breast cancer metastasis: A Swedish cohort study

Cancer medicine (Malden, MA), 2023-05, Vol.12 (9), p.10840-10850

2023

Volltextzugriff (PDF)

Sickness absence and disability pension among swedish women prior to breast cancer relapse with a special focus on the roles of treatment and comorbidity

European journal of cancer care, 2021-01, Vol.30 (1), p.e13353-n/a

2021

Volltextzugriff (PDF)

Distribution of biomarker evaluation scores among the pathology departments of Sweden: Comparison study of 35,066 breast cancer cases

CANCER RESEARCH, 2020, Vol.80 (4)

2020

Volltextzugriff (PDF)

Coping with expensive drugs around the world

EJC SUPPLEMENTS, 2008, Vol.6 (7), p.51-51

2008

Volltextzugriff (PDF)

There is more to the picture than meets the eye: Population-based study on biopsy verification of suspected breast cancer recurrences

JOURNAL OF CLINICAL ONCOLOGY, 2015, Vol.33 (15_suppl), p.542-542

2015

Volltextzugriff (PDF)

Abstract P1-09-05: Re-Testing of HER2 Status in Recurring Metastatic Breast Cancer Is a Clinically Relevant and Cost-Effective Strategy

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P1-P1-09-05

2010

Volltextzugriff (PDF)

Abstract P6-06-17: Gene signature model predicts metastatic onset better than standard clinical markers - Nested case-control design uniquely enables enrichment for biologically relevant features

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P6-P6-06-17

2013

Volltextzugriff (PDF)

Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden

Acta oncologica, 2010-08, Vol.49 (6), p.844-850

2010

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(67)
Tagungsberichte
(21)

Sprache

Erscheinungsjahr

n.n

Thema

Medicin Och Hälsovetenskap
(43)
Science & Technology
(39)
Life Sciences & Biomedicine
(33)
Humans
(27)
Oncology
(23)
Female
(21)
Middle Aged
(16)
Biological And Medical Sciences
(15)
Medical Sciences
(14)
Aged
(12)
Breast Cancer
(9)
Breast Neoplasms - Drug Therapy
(8)
Follow-Up Studies
(8)
Tumors
(8)
Adult
(7)
Combined Modality Therapy
(7)
Pharmacology. Drug Treatments
(7)
Physical Sciences
(7)
Breast Neoplasms - Mortality
(6)
Hematology, Oncology And Palliative Medicine
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The value of anticancer drugs - a regulatory view

5024 POSTER DISCUSSION Clinically Used Breast Cancer Markers are Heterogeneous Throughout Tumour Progression

Discordance in hormone receptor status in breast cancer during tumor progression

Uptake of aromatase inhibitors (AI) and trastuzumab (T) during the first 5 years after market introduction. A North American and European comparison

Abstract S3-5: Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression

Inter- and intra-country variations in the use of trastuzumab in Norway, Spain and Sweden

HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients

398 INVITED Should a Biopsy Be Done in Each Patient With a Suspicion of Metastatic Relapse?

Does access to cancer drugs relate to survival benefit? A European study in countries with different economic status

Access to cancer drugs in Europe years 2005-2014

Access to cancer drugs in Europe years 2005-2014

Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression

Risk-adjusted benchmarking of long-term overall survival in patients with HER2-positive early-stage Breast cancer: A Swedish retrospective cohort study

Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

540 Uptake of trastuzumab (T) in selected European countries during the first 9 years after market introduction

Use of sickness benefits by patients with metastatic breast cancer—A Swedish cohort study

Planning for return to work during the first year after breast cancer metastasis: A Swedish cohort study

Sickness absence and disability pension among swedish women prior to breast cancer relapse with a special focus on the roles of treatment and comorbidity

Distribution of biomarker evaluation scores among the pathology departments of Sweden: Comparison study of 35,066 breast cancer cases

Coping with expensive drugs around the world

There is more to the picture than meets the eye: Population-based study on biopsy verification of suspected breast cancer recurrences

Abstract P1-09-05: Re-Testing of HER2 Status in Recurring Metastatic Breast Cancer Is a Clinically Relevant and Cost-Effective Strategy

Abstract P6-06-17: Gene signature model predicts metastatic onset better than standard clinical markers - Nested case-control design uniquely enables enrichment for biologically relevant features

Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden

Suchergebnisse filtern